Business Context and Reporting Period
This Form 8-K Current Report was filed by Silexion Therapeutics Corp on July 31, 2026. The registrant is incorporated in the Cayman Islands with principal executive offices in Ramat-Gan, Israel. The report discloses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is the resignation of a director:
- Resignation: Professor Amnon Peled resigned from the Board of Directors.
- Effective Date: August 1, 2026.
- Reason: Personal reasons.
- Disagreement: The resignation did not arise from any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on strategy, or specific risk factors beyond the standard disclosure of the director's departure.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the August 1, 2026 effective date of Professor Peled's resignation.
- Confirm whether the Company intends to appoint a replacement director and the timeline for such an appointment.
- Review subsequent filings for any impact on the Company's strategic direction or operational oversight.